Description of Assertio Holdings Inc's Business Segments
Assertio Holdings Inc. operates through two distinct segments: Specialty Pharmaceuticals and Contract Manufacturing, each contributing uniquely to the company’s overall operations and strategic objectives. Below is an extensive overview of these segments, the products offered, and the services provided.
Segments
Specialty Pharmaceuticals The Specialty Pharmaceuticals segment is at the core of Assertios mission, focusing on the commercialization of branded prescription products primarily within the fields of neurology, orphan diseases, and specialized therapeutic areas. This segment manages a diverse portfolio of products, which are designed to cater to the unique needs of patients dealing with complex health conditions. Assertio is dedicated to driving value in this segment by continually exploring innovative treatments and building a robust pipeline of products aimed at underserved patient populations.
Key Products in the Specialty Pharmaceuticals Segment:
- Gralise: An antiepileptic agent, Gralise is utilized for treating postherpetic neuralgia (PHN), which is characterized by nerve pain following shingles. Gralise allows patients to manage chronic pain more effectively and has been positively received due to its targeted therapeutic approach.
- Cambia: This non-steroidal anti-inflammatory drug (NSAID) is specifically indicated for the treatment of acute migraine attacks, with or without aura, in adult patients. Cambia offers rapid relief for patients experiencing the debilitating effects of migraines.
- Lazanda: A fentanyl nasal spray designed for managing breakthrough pain in adults with cancer who already exhibit a level of tolerance to opioid therapies. Lazanda provides an effective means of addressing sudden, intense pain episodes, enhancing quality of life for patients in critical care situations.
- Zipsor: Another NSAID in Assertio’s portfolio, Zipsor is utilized for the relief of mild to moderate pain. It serves as an accessible option for pain management across various settings.
Contract Manufacturing The Contract Manufacturing segment of Assertio Holdings specializes in the manufacture and distribution of externally developed pharmaceutical products, with a distinct emphasis on controlled substances. This segment leverages Assertios expertise in advanced manufacturing techniques and quality assurance processes to ensure that the products meet stringent regulatory standards.
Key Functions in the Contract Manufacturing Segment:
- Manufacturing: Assertio’s state-of-the-art manufacturing facilities enable the production of both controlled substances and generic products. The company offers comprehensive active pharmaceutical ingredient (API) manufacturing services, ensuring quality and consistency in the production process.
- Analytical Services: Assertio provides a range of analytical services to support its manufacturing operations. These include method development and validation, stability studies, impurity identification, and more, all crucial for ensuring that products meet safety and efficacy standards.
- Development Activities: The development arm of the Contract Manufacturing segment includes formulation development, pre-formulation studies, and process development. Assertio focuses on optimizing manufacturing processes, conducting scale-up operations, and facilitating tech transfers, which are essential for bringing new products to market efficiently and successfully.
Summary Assertio Holdings Inc. is well-positioned in both the Specialty Pharmaceuticals and Contract Manufacturing segments, combining therapeutic development and advanced manufacturing capabilities. With a commitment to innovation and quality, Assertio aims to address critical healthcare needs while supporting the pharmaceutical industrys demand for high-quality, compliant manufacturing solutions. The company’s diverse product offerings and service capabilities underline its strategic focus on enhancing patient care and operational excellence.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
89.58 %